NEW AGENTS FOR PNEUMOCYSTIS CARINII PNEUMONIA
治疗卡氏肺囊虫肺炎的新药
基本信息
- 批准号:6335829
- 负责人:
- 金额:$ 3.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1977
- 资助国家:美国
- 起止时间:1977-06-01 至 2004-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Pneumocystis carinii pneumonia (PCP) is the most common serious
opportunistic infection in patients with acquired immunodeficiency
syndrome (AIDS) and as a major cause of mortality in these patients.
Pentamidine is one of the drugs of choice widely used for the treatment of
AIDS-related PCR despite its high incidence of serious side effects.
Therefore, the is a critical need for more effective and less toxic anti-PCP
agents. Pentamidine is a flexible molecule and can assume a number of
interconvertible conformations. The precise mechanism of anti-PCP
action of pentamidine is unknown. We hypothesize that the
conformational flexibility of pentamidine allows it to bind to different
macromolecules and this may account at least in part, for the therapeutic
as well as toxic actions of the drug. It may therefore, be possible to
separate these actions by a conformation-biological activity relationship
study. To test these hypothesis, we propose to conduct the following
studies: a) design and synthesize new conformationally restricted
analogues related to pentamidine; b) determine the pKa values of the
synthesized compounds; c) evaluate the compounds for in vitro anti-PCP
activity and toxicity in an animal model of the disease; e) study the
interactions of the proposed pentamidine analogues with DNA using
molecular modeling techniques and by measuring thermal denaturation
temperatures. The information gained will be valuable not only in
determining the mechanism(s) of action of the pentamidine analogues, but
may also result in the development of a more effective and safer anti-PCR
agent.
卡氏肺囊虫肺炎(PCP)是最常见的严重疾病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TIEN L HUANG其他文献
TIEN L HUANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TIEN L HUANG', 18)}}的其他基金
Novel Pentamidine Congeners as Anti-opportunistic and Anti-parasitic Agents
作为抗机会药物和抗寄生虫药物的新型喷他脒同系物
- 批准号:
6727036 - 财政年份:2004
- 资助金额:
$ 3.85万 - 项目类别:
ANTI-PCP AGENTS FOR ALCOHOLIC AIDS PATIENTS
用于酒精艾滋病患者的抗 PCP 药物
- 批准号:
6104048 - 财政年份:1997
- 资助金额:
$ 3.85万 - 项目类别:
Novel Pentamidine Congeners as Anti-opportunistic and Anti-parasitic Agents
作为抗机会药物和抗寄生虫药物的新型喷他脒同系物
- 批准号:
7405328 - 财政年份:
- 资助金额:
$ 3.85万 - 项目类别:
相似海外基金
Development of a vaccine to prevent Pneumocystis pneumonia
开发预防肺孢子虫肺炎的疫苗
- 批准号:
9906567 - 财政年份:2020
- 资助金额:
$ 3.85万 - 项目类别:
Pathogenesis of spontaneous pneumocystis pneumonia in Caspase8 and Ripk3 double deficient mice
Caspase8和Ripk3双缺陷小鼠自发性肺孢子虫肺炎的发病机制
- 批准号:
19K17650 - 财政年份:2019
- 资助金额:
$ 3.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection
在 HIV 感染的非人灵长类动物模型中治疗肺孢子虫肺炎的治疗性抗体
- 批准号:
10001636 - 财政年份:2018
- 资助金额:
$ 3.85万 - 项目类别:
Therapeutic antibodies to treat Pneumocystis pneumonia in a nonhuman primate model of HIV infection
在 HIV 感染的非人灵长类动物模型中治疗肺孢子虫肺炎的治疗性抗体
- 批准号:
9624861 - 财政年份:2018
- 资助金额:
$ 3.85万 - 项目类别:
Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
维生素 D 作为肺孢子菌肺炎的补充疗法
- 批准号:
9063354 - 财政年份:2016
- 资助金额:
$ 3.85万 - 项目类别:
Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
维生素 D 作为肺孢子虫肺炎的补充疗法
- 批准号:
9238656 - 财政年份:2016
- 资助金额:
$ 3.85万 - 项目类别:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
改进肺孢子虫肺炎的治疗和诊断
- 批准号:
10521311 - 财政年份:2016
- 资助金额:
$ 3.85万 - 项目类别:
Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia
改进肺孢子虫肺炎的治疗和诊断
- 批准号:
9210593 - 财政年份:2016
- 资助金额:
$ 3.85万 - 项目类别: